Investigation of Immune Checkpoint Inhibitors in Bladder Cancer: Novel Therapeutics and Mechanisms of Resistance

Project: Research project

Project Details

Description

Bladder cancer is the fourth most common cancer in men and fifth most common overall. Despite improvements in chemotherapy, surgery and “personalized medicine” directed at tumor-specific mutations, the survival for bladder cancer is unchanged over the last 50 years. Patients with non-muscle invasive bladder cancer have a 70% risk of recurrence of their tumor at 5 years and those with muscle-invasive cancer have only a 50% survival 5 years after radical cystectomy and chemotherapy. Thus, there is an urgent need for novel therapies to improve treatment for patients with all stages of urothelial carcinoma.
StatusActive
Effective start/end date6/29/172/28/22

Funding

  • NextCure, Inc. (Agmt 6/29/17)

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.